Physician profile
Kelsey Rutter
NPI 1518686674
$3,228.47
in general payments reported to CMS, 2019-2025
42 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $242 · 2024: $1,724 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $413.11 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $336.49 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $194.72 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $176.78 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $154.26 | 2024-2025 | Sunosi, Auvelity |
| Exact Sciences Corporation | $148.98 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $134.08 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.77 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $117.85 | 2023-2025 | |
| Novo Nordisk INC | $111.20 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.72 | 2024-2025 | Caplyta |
| Lundbeck LLC | $104.12 | 2024-2025 | Rexulti, Vyepti |
| Inspire Medical Systems, INC. | $101.07 | 2023 | Inspire |
| Amgen INC. | $78.98 | 2023-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $70.34 | 2024 | Dexcom G6 Transmitter |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $69.78 | 2023-2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $59.52 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $58.66 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $51.58 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.01 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.90 | 2024-2025 | Jardiance |
| Abbvie INC. | $43.29 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.64 | 2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $39.85 | 2024-2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $38.00 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $37.37 | 2025 | Veozah |
| Genzyme Corporation | $33.96 | 2024 | |
| Corcept Therapeutics | $31.45 | 2024 | Korlym |
| Verrica Pharmaceuticals INC. | $28.53 | 2025 | Ycanth |
| Abbott Laboratories | $25.00 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Xeris Pharmaceuticals, INC. | $23.25 | 2024 | Recorlev |
| Antares Pharma, INC. | $21.43 | 2024 | Xyosted |
| Sanofi-Aventis U.S. LLC | $20.23 | 2023 | |
| Tris Pharma INC | $18.49 | 2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $17.00 | 2024 | Xarelto |
| Medtronic, INC. | $16.67 | 2023 | Intellis Adaptivestim |
| Eisai INC. | $15.90 | 2024 | |
| Abiomed | $15.87 | 2024 | Impella |
| Sanofi Pasteur INC. | $14.20 | 2025 | |
| Galderma Laboratories, L.P. | $13.26 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2024 | Livalo |
| Organon LLC | $11.99 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Rutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.